Appointment dossier — Small Cell Carcinoma

Compounds studied in Small Cell Carcinoma

• Carboplatin — Review evidence · 0 positive / 1 negative-mixed · PMID 40129783, 37485216
• Cisplatin — Review evidence · 0 positive / 1 negative-mixed · PMID 18408396
• Durvalumab — Review evidence · 0 positive / 1 negative-mixed · PMID 40129783, 37485216
• Etoposide — Review evidence · 0 positive / 2 negative-mixed · PMID 40129783, 37485216, 18408396

“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.

Open recruiting trials (18)

• NCT06161532 · Phase 2 — Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... (United States)
• NCT05173246 · Phase 2 — JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma (China)
• NCT07070518 · Phase 1 / Phase 2 — Study of GV20-0251 in Participants With Solid Tumor Malignancies (China)
• NCT06652607 — PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer (Italy)
• NCT03851445 · Phase 2 / Phase 3 — Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer (United States)
• NCT07362459 · Phase 3 — A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. (China)
• NCT05800223 · Phase 3 — Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer (China)
• NCT06954246 · Phase 3 — A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (China)
• NCT07500701 · Phase 3 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer (South Korea)
• NCT06592924 · Phase 3 — Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (United States)
• NCT05381103 · Phase 2 / Phase 3 — PSMA-PET to Guide Prostatectomy (United States)
• NCT06465329 · Phase 2 — A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) (United States)
• NCT06497530 · Phase 2 — Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC (China)
• NCT04210492 · Phase 1 / Phase 2 — Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer (United States)
• NCT05168566 · Phase 2 — Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer (United States)
• NCT04144569 · Phase 2 — PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC (China)
• NCT05913089 · Phase 2 — A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer (China)
• NCT06067269 · Phase 2 — Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial (United States)

Most-relevant first: trials that name Small Cell Carcinoma, then broader trials you may still qualify for. 1520 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.

Financial help to look into

• PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
• HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
• CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
• Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
• NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/

For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.

Questions to ask your oncologist

1. Of the open trials I found (for example NCT06161532), am I eligible for any — here or at a larger cancer center?
2. What is my exact diagnosis — the type, subtype, stage, and grade?
3. Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
4. Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
5. What is the goal of treatment for me — cure, long-term control, or comfort?
6. What are all of my standard treatment options, and what does each one involve?
7. What is the realistic benefit of each option, in actual numbers?
8. What are the most common and the most serious side effects, and how are they managed?
9. How will we know if treatment is working, and how often will I be scanned or tested?
10. If the first treatment doesn't work, what are the next options?
11. Are there gentler options if I want to prioritize quality of life?
12. Am I eligible for any clinical trials — here or at a larger/academic cancer center?
13. Is my case reviewed by a multidisciplinary tumor board?
14. Would a second opinion at a center that treats my cancer often be worthwhile?
15. Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
16. Which symptoms are emergencies, and who do I call after hours?
17. Should I see palliative or supportive care alongside my treatment?
18. How will treatment affect my daily life, work, and (if it matters to me) fertility?
19. What can I safely do myself — diet and activity — and is anything I'm taking risky?
20. What will treatment cost, and is financial assistance available?
21. Should my tumor tissue be stored (biobanked) for future testing or trials?